| 纳米氢氧化镧对大鼠慢性肾衰竭致高磷血症的治疗作用 |
| |
| 引用本文： | 赵璐璐,马子兴,俞腾飞,武燕,刘丹丹,张晓菲,苗鑫,邢海燕,李刚. 纳米氢氧化镧对大鼠慢性肾衰竭致高磷血症的治疗作用[J]. 中国现代应用药学, 2019, 36(12): 1449-1455 |
| |
| 作者姓名： | 赵璐璐 马子兴 俞腾飞 武燕 刘丹丹 张晓菲 苗鑫 邢海燕 李刚 |
| |
| 作者单位： | 内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100,内蒙古医科大学, 呼和浩特 010100 |
| |
| 基金项目： | 国家自然科学基金项目（81560685） |
| |
| 摘 要： | 目的 研究纳米氢氧化镧对大鼠慢性肾衰竭致高磷血症的治疗作用，并与碳酸镧和普通粒径氢氧化镧的治疗作用进行比较。方法 建立纳米氢氧化镧的合成工艺，通过腺嘌呤（0.2 g·kg-1）对60只Wistar大鼠建立慢性肾衰竭高磷血症动物模型，随机分为纳米氢氧化镧高、中、低剂量组（0.15，0.1，0.05 g·kg-1）、碳酸镧组（0.3 g·kg-1）、普通粒径氢氧化镧组（0.1 g·kg-1）和模型组。另取20只Wistar大鼠，随机分为空白组和纳米氢氧化镧空白给药组。检测血清磷、尿液磷、血清肌酐、尿液肌酐、血尿素氮、尿液尿素氮、肾脏系数、甲状旁腺激素等生化指标，比较纳米氢氧化镧与普通磷结合剂对于高磷血症的治疗作用。结果 与模型组比较，纳米氢氧化镧（0.1 g·kg-1）对高磷血症大鼠中的血清磷、血清肌酐、尿液尿素氮、肾脏系数有降低作用并且有显著性差异（P<0.05）；与碳酸镧和普通粒径氢氧化镧相比有降低作用，但没有显著性差异。结论 纳米氢氧化镧与碳酸镧相比具有更高的效价，可以作为后续开发的新型磷结合剂。
|
| 关 键 词： | 肾衰竭 高磷血症 纳米氢氧化镧 碳酸镧 |
| 收稿时间： | 2018-07-20 |
| 修稿时间： | 2019-06-03 |
Therapeutic Effect of Nano-lanthanum Hydroxide on Rats with Hyperphosphatemia Induced by Chronic Renal Failure |
| |
| ZHAO Lulu,MA Zixing,YU Tengfei,WU Yan,LIU Dandan,ZHANG Xiaofei,MIAO Xin,XING Haiyan and LI Gang. Therapeutic Effect of Nano-lanthanum Hydroxide on Rats with Hyperphosphatemia Induced by Chronic Renal Failure[J]. The Chinese Journal of Modern Applied Pharmacy, 2019, 36(12): 1449-1455 |
| |
| Authors: | ZHAO Lulu MA Zixing YU Tengfei WU Yan LIU Dandan ZHANG Xiaofei MIAO Xin XING Haiyan LI Gang |
| |
| Affiliation: | Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China,Inner Mongolia Medical University, Hohhot 010100, China and Inner Mongolia Medical University, Hohhot 010100, China |
| |
| Abstract: | OBJECTIVE To observe the therapeutic effects of nano-lanthanum hydroxide(Nano-LH) on hyperphosphatemia rats, and to compare the therapeutic effects with lanthanum carbonate and common particle size lanthanum hydroxide. METHODS A synthetic process of Nano-LH was established. Animal model of hyperphosphatemia in 60 Wistar rats with chronic renal failure was established by adenine(0.2 g·kg-1), and the model rats were randomly divided into high, middle and low dose groups of Nano-LH(0.15, 0.1, 0.05 g·kg-1), lanthanum carbonate group(0.3 g·kg-1), normal particle size lanthanum hydroxide group(0.1 g·kg-1) and model group. Another 20 Wistar rats were randomly divided into blank control group and blank administration group of Nano-LH. Biochemical indicators such as serum phosphorus, urine phosphorus, serum creatinine(Scr), urine creatinine, blood urea nitrogen(BUN), urine urea nitrogen, kidney index(KI) and parathyroid hormone were examined and the therapeutic effects of Nano-LH and common renagel on hyperphosphatemia were compared. RESULTS Compared with the model group, Nano-LH(0.1 g·kg-1) had a lowering effect on serum phosphorus, Scr, BUN and KI in the hyperphosphatemia rats with significant differences(P<0.05). And it had a lowering effect than lanthanum carbonate and normal partical size lanthanum hydroxide, but there was no significant difference. CONCLUSION Nano-LH has higher potency than lanthanum carbonate, and can be a new phosphorus binder developed later. |
| |
| Keywords: | chronic renal failure hyperphosphatemia nano-lanthanum hydroxide canthanum hydroxide |
|
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 |
|
点击此处可从《中国现代应用药学》下载全文 |
|
